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The pathogenesis of cystic nephroma of the kidney has interested pathologists for over 50 years. Emerging from its
initial designation as a type of unilateral multilocular cyst, cystic nephroma has been considered as either a
developmental abnormality or a neoplasm or both. Many have viewed cystic nephroma as the benign end of the
pathologic spectrum with cystic partially differentiated nephroblastoma and Wilms tumor, whereas others have
considered it a mixed epithelial and stromal tumor. We hypothesize that cystic nephroma, like the pleuropulmonary
blastoma in the lung, represents a spectrum of abnormal renal organogenesis with risk for malignant
transformation. Here we studied DICER1 mutations in a cohort of 20 cystic nephromas and 6 cystic partially
differentiated nephroblastomas, selected independently of a familial association with pleuropulmonary blastoma
and describe four cases of sarcoma arising in cystic nephroma, which have a similarity to the solid areas of type II
or III pleuropulmonary blastoma. The genetic analyses presented here confirm that DICER1 mutations are the major
genetic event in the development of cystic nephroma. Further, cystic nephroma and pleuropulmonary blastoma
have similar DICER1 loss of function and ‘hotspot’ missense mutation rates, which involve specific amino acids in
the RNase IIIb domain. We propose an alternative pathway with the genetic pathogenesis of cystic nephroma and
DICER1-renal sarcoma paralleling that of type I to type II/III malignant progression of pleuropulmonary blastoma.
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Cystic nephroma of the kidney originally emerged as
a specific entity from a group of lesions with the
collective designation of unilateral multilocular
cyst; one of the early references regarding unilateral
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1956.1 The past 50 years have provided little further
insight into its histogenesis, although childhood
cystic nephroma and cystic partially differentiated
nephroblastoma have been regarded as part of the
spectrum of Wilms tumor.2,3
The current study is based in part on the
observation of an apparent familial association of
cystic nephroma and the pulmonary neoplasm of
childhood, pleuropulmonary blastoma.4–6 These
findings were confirmed in studies from the
International Pleuropulmonary Blastoma Registry
(Registry), noting that B12% of children with a
pleuropulmonary blastoma also had a cystic nephro-
ma or a family member with cystic nephroma.7 Since
the latter report, much has been learned about the
genetic pathogenesis of pleuropulmonary blastoma.
Using linkage analysis, Hill and associates detected
heterozygous germline loss-of-function mutations of
the miRNA processing gene DICER1 in 11
pleuropulmonary blastoma families; one of the
individuals in this initial linkage study had a
cystic nephroma.8 Subsequent analyses demon-
strate that 80/122 (65.5%) children with pleuro-
pulmonary blastoma have heterozygous germline
loss-of-function DICER1 mutations (unpublished
data). Tumors in the DICER1-pleuropulmonary
blastoma familial tumor predisposition syndrome
appear to follow a two-hit model of tumorigenesis.
Analysis of pleuropulmonary blastoma tumor tissue
identified deleterious somatic missense mutations in
the second (normal) DICER1 allele involving very
specific regions or ‘hotspots’ in the RNase IIIb
domain.9 These RNase IIIb mutations, or second
‘hits’, lead to defective cleavage of the mature
miRNA from the 5p arm of the miRNA hairpin,
resulting in tumor-specific loss of the major subset of
miRNAs in the tumors.9 These missense mutations
appear to occur very early in tumorigenesis with
subsequent genetic events involving p53 function
and RAS pathway activation contributing to
pleuropulmonary blastoma tumor progression.
Similar DICER1 somatic mutations were identified
in 26 of 43 (60%) Sertoli-Leydig tumors of the
ovary.10 Sertoli-Leydig tumors are seen in the
DICER1-pleuropulmonary blastoma familial tumor
predisposition syndrome.11
The present report documents our findings of
DICER1 mutations in a cohort of 20 cystic nephro-
mas and 6 cystic partially differentiated nephro-
blastomas that were selected independently of a
familial association with pleuropulmonary blastoma
and also includes a clinicopathologic review of 34
individuals with cystic nephroma from the Registry.
In addition, we describe four cases of a primary
sarcoma arising in cystic nephroma that have
remarkably similar histologic features to the solid
sarcomatous patterns of type II/III pleuropulmonary
blastoma. This genetic analysis of cystic nephroma
provides some histogenetic and nosologic clarity
while at the same time prompting new questions
about the biology and natural history of cystic
nephroma.
Materials and methods
Patients/Samples
DNA from 16 and 8 snap frozen cystic nephroma and
cystic partially differentiated nephroblastoma,
respectively, and formalin-fixed, paraffin-embedded
tissue scrolls on an additional two cystic nephromas
were obtained from the Cooperative Human Tissue
Network from children enrolled on Children’s Oncol-
ogy Group protocols from 2007 to 2010. Pathology
reports without identifying information were ob-
tained for each specimen and included age, sex, site
of tissue and a pathologic description. No additional
patient history or follow-up was provided. Access to
Cooperative Human Tissue Network samples was
approved through an application submitted to the
Children’s Oncology Group Renal Tumor Biology
Section, and this research was approved by the
Institutional Review Board at Children’s National
Medical Center, Washington, DC, USA. Paraffin
blocks from an additional 11 cystic nephromas and
four renal sarcomas were obtained from the Registry
or from the authors’ consultation files (DAH, LPD,
PF, EP). For all formalin-fixed, paraffin-embedded
samples, four 10-micron scrolls were prepared from a
tumor block. Following paraffin removal, DNA was
extracted using the Maxwell 16 Formalin-Fixed
Paraffin Embedded Tissue LEV DNA Purification
Kit (Promega, Madison, WI, USA) on the Maxwell 16
Instrument (Promega). DNA quality and quantity was
assessed using a Nanodrop (ThermoFisher, Wilming-
ton, DE, USA) and Qubit (Qubit 2.0, Life Technolo-
gies, Carlsbad, CA, USA), respectively.
Next Generation Sequencing and Analysis
Formalin-fixed, paraffin-embedded and fresh DNA
samples were sequenced with the Ion Torrent
Personal Genome Machine (Life Technologies) using
standard protocols. A custom multiplex polymerase
chain reaction panel was designed for the coding
regions of DICER1 with an average amplicon length
less than 200 base pairs (Custom Ampliseq, Life
Techologies). The initial polymerase chain reaction
amplification was performed on 10ng of starting
DNA. The resulting amplicons were then barcoded
and ligated to adaptors (Ion Ampliseq Library kit
2.0, Life Technologies). Templates were prepared
using the Ion Personal Genome Machine Template
OT2 200 prep kit and the One Touch 2 system (Life
Technologies). Sequencing was performed on a 318
chip (ION Sequencing 200 kit V2, Life Technologies)
with an average of six samples per chip plus one
each positive and negative control samples to
achieve an average depth of coverage of 3000 filtered
reads. Signal processing, mapping and quality
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(Life Technologies). Variant calls were made using
Torrent Variant Caller Plugin 3.4 choosing
somatic mutation workflow and default settings.
BAM files containing raw reads were reviewed
using Integrative Genomics Viewer http://www.
broadinstitute.org/software/igv/home.12,13 Variants
were annotated with Ion Reporter Software and
named using HUGO nomenclature for DICER1
transcript NM_177438.2.14 Nonsense and
frameshift mutations were classified as ‘allele loss
of function.’ Missense variants affecting codons for
amino acids 1705, 1709, and 1809, 1810, 1813, and
1814 were classified as ‘hotspot mutations.’ Allele
frequency was recorded for each variant. Coverage
information was recorded for each of the cases with
normal sequence at all hotspot bases. SIFTwas used
to assess the potential significance of predicted
novel amino-acid substitutions outside of the
hotspot regions http://sift-dna.org.15,16
Sanger Sequencing
For the DNA samples derived from fresh/frozen
tumors, high throughput Sanger sequencing was
performed on all coding exons and intron–exon
junctions in the DICER1 gene (BeckmanCoulter
Genomics, Danvers, MA, USA). The sequence traces
were assembled and the chromatograms were
scanned for variants using Mutation Surveyor ver-
sion 4.0.6 (Soft Genetics, State College, PA, USA).
For two formalin-fixed, paraffin embedded sarcoma
cases, primer pairs for smaller amplicons containing
the hotspot sequences were used: Primer pair 1:
Forward: 50-tggggatcagttgctatgtg-30 and Reverse: 50-C
GGGTCTTCATAAAGGTGCT-30; Primer pair 2: For-
ward: 50-tggactgcctgtaaaagtgg-30 and Reverse: 50-ATG
TAAATGGCACCAGCAAG-30.
Results
Patient Characteristics of the Cooperative Human
Tissue Network Cohort
Review of the microscopic descriptions from the
pathology reports for two cases submitted as cystic
partially differentiated neoplasm to the Cooperative
Human Tissue Network bank indicated no primitive
nephroblastic elements. Central review was per-
formed by the pathologist (EP) with access to
pathologic slides but blinded to genetic data who
indicated that these tumors did not contain primi-
tive nephroblastic elements, and thus are consid-
ered cystic nephromas in the analysis. The 20
patients with cystic nephromas ranged from 1
month to 106 months at diagnosis (median 16
months) and there were 11 females and 9 males.
Ten tumors involved the right kidney, eight involved
the left and for two the side was unknown. The six
patients with cystic partially differentiated nephro-
blastomas ranged in age from 4 to 14 months
(median 7 months). Four of six patients were female.
Four of the six tumors were right sided.
DICER1 Sequencing of the Cooperative Human Tissue
Network Cohort
The sequencing results of the Cooperative Human
Tissue Network cohort are provided in Table 1.
Allelic loss of function DICER1 mutations were seen
in 14/20 (70%) cystic nephromas and 0/6 (0%)
cystic partially differentiated nephroblastomas,
respectively. The loss of function mutations in-
cluded nine insertion-deletions with frameshifts,
four nonsense mutations and one c.2437-1G4A
substitution involving the canonical splice site of
intron 18-exon19. Each of these mutations result in
premature truncation of the DICER1 protein (deleter-
ious truncating mutations) An additional loss of
function variant in one of the cystic nephromas was
three bases proximal to the intron 25-exon 26
junction c.5527þ3A4G (intron 25) (Table 1). No
RNAwas available to determine if this variant would
disrupt normal splicing. Germline DNA was not
initially requested at the start of this study; hence,
we were unable to determine whether these loss of
function mutations were germline or somatic. (How-
ever, the majority (80%) of loss of function mutations
are germline in the pleuropulmonary blastoma).9
Deleterious missense DICER1 mutations affecting
one of the six amino-acid hotspots were seen in 18/
20 (90%) cystic nephromas and 0/6 cystic partially
differentiated nephroblastomas, respectively (Fisher
exact test two-tailed P¼0.0001). The most frequent
amino acid affected by mutations was amino acid
1813 (nine cases). Mutations altering amino acids
1705 and 1709 were seen in three cases each. There
were two mutations affecting amino acid 1809 and
one affecting amino acid 1810.
Eleven of 14 (79%) deleterious truncating muta-
tions had allele frequencies between 43 and 54%
which would be within range of the expected 50%
for a heterozygous germline mutation. One truncat-
ing mutation had a low frequency of 15%, which
may indicate either loss of this allele in the tumor
was the second event (this tumor also had 38%
allele frequency hotspot) or the truncating mutation
in this allele was accompanied by duplication of the
hotspot missense mutant allele (see below). The
allele frequencies for hotspot missense mutations
were widely variable ranging from 1 to 53% (median
23%), which likely reflects the variability in
mesenchymal content of each sampled tissue, as it
would be unexpected in a cystic nephroma sample
to have 100% tumor cellularity given the common-
place presence of inflammatory cells, fibroblasts and
normal renal parenchyma. Thus, in the one case of
cystic nephroma with 53% hotspot allele frequency,
it is likely that there has been gain of the hotspot
missense allele, which has been described in
Modern Pathology (2014) 27, 1267–1280
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confirmed next generation sequencing results with
the exception of variants with allele frequencies less
than 10%.
Patient Characteristics of Cystic Nephromas and
Wilms Tumors in Registry Families
The Registry has collected and analyzed clinical,
pathological and treatment data on 375 children
with pleuropulmonary blastoma and additional
patients and family members with related condi-
tions.5 To date, thirty-four cases of cystic nephroma
have been identified including 19 cases occurring in
children with pleuropulmonary blastoma, 8 in
family members of children with pleuropulmonary
blastoma and 7 in children who presented with
cystic nephroma alone (Table 2). In this group, 18
patients had DICER1 testing performed and 13/18
(72%) had a loss of function (truncating) germline
mutation. The median age at diagnosis was 19
months, (range 0–54 months), with one outlier
diagnosed at 179 months. Available information on
those cases of cystic nephroma disclosed that 74%
were unilateral and 26% were bilateral. Treatment
included complete nephrectomy in most cases
(n¼18), partial nephrectomy (n¼8), one left
nephrectomy with contralateral partial nephrect-
omy, and two patients required bilateral nephrect-
omy followed by transplantation.17 With a median
follow-up of 4.6 years (range 0–47 years), two
patients died (2/34 or 6%) and both from the
progression of their pleuropulmonary blastomas.
Of the 34 patients with cystic nephromas, 6 (18%)
had type II pleuropulmonary blastoma and 13 (39%)
had a type I pleuropulmonary blastoma and/or
radiographic evidence of lung cysts. One case with
bilateral cystic nephromas diagnosed at 11 months
of age had a left nephrectomy with progressive
enlargement of cysts in the right kidney; this patient
developed a cystic (type I) pleuropulmonary blas-
toma at 19 months of age requiring chemotherapy.
The growth of the renal cysts appeared to be arrested
during the chemotherapy. Clinical follow-up at 4.5
years indicates that this patient remains healthy
with stable renal cysts and normal renal function.
The Registry cohort includes four cases of Wilms
tumor; one in a child who later developed pleur-
opulmonary blastoma and the remaining three in
relatives of children who had pleuropulmonary
blastomas (mother, brother, and great uncle). Of
note, the mother with Wilms tumor in childhood
did not have a DICER1 mutation, whereas her child
with pleuropulmonary blastoma inherited her germ-
line truncating DICER1 mutation from the paternal
Table 1 DICER1 variants in cystic nephromas obtained from cooperative human tissue network
Publication ID DX Loss of function mutation ‘Hotspot’ missense mutation
CN1 CN c.1525C4T; p.Arg509a c.5438A4G; p.Glu1813Gly
CN2 CN c.2928C4A; p.Tyr976a c.5439G4T;p.Glu1813Asp
CN3 CN c.2965_2968dupGATG; p.Val990Glyfsa10 c.5425G4A; p.Gly1809Arg
CN4 CN c.2448dupT; p.Pro817Serfsa14 c.5113G4A; p.Glu1705Lys
CN5 CN c.2437-1G4A (intron 18-exon19) splice c.5113G4A; p.Glu1705Lys
CN6 CN c.1284_1285delGA; p.Lys429Alafsa47 c.5439G4T; p.Glu1813Asp
CN7 CN c.3033_3045delGCTTCCTTTAAGC p.Leu1012Valfsa50 c.5439G4T; p.Glu1813Asp
CN8 CN c.3091C4T; p.Gln1031a c.5428G4C; p.Asp1810His
CN9 CNa c.3970_3971delAAinsC; p.Lys1324Argfsa23 c.5425G4A; p.Gly1809Arg
CN10 CN c.4004dupA; p.Tyr1335a c.5437G4A; p.Glu1813Lys
CN11 CN c.745delC; p.Gln249Serfsa23 c.5438A4G; p.Glu1813Gly
CN12 CN c.1189_1190delAG: p.Ser396Argfsa c.5113G4A; p.Glu1705Lys
CN13 CN c.5333_5333delA; pGlu1778Glyfsa c.5125G4A; p.Asp1709Asn
CN14 CN c.4007delC; p.Pro1336Leufsa11 c.5125G4A; p.Asp1709Asn
CN15 CN c.5527þ3A4G (intron 25) c.5439G4T; p.Glu1813Asp
CN16 CN Negative c.5438A4G; p.Glu1813Gly
CN17 CNa Negative c.5439G4T; p.Glu1813Asp
CN18 CN Negative c.5125G4A; p.Asp1709Asn
CN19 CN Negative Negative
CN20 CN Negative Negative
CPDN1 CPDN Negative Negative
CPDN2 CPDN Negative Negative
CPDN3 CPDN Negative Negative
CPDN4 CPDN Negative Negative
CPDN5 CPDN Negative Negative
CPDN6 CPDN Negative Negative
Abbreviations: CN: cystic nephroma; CPDN: cystic partially-differentiated nephroblastoma; DX: diagnosis; ND: not determined; #reads: average
#reads over all hotspot amino acids is provided for negative casesGenetic variants are displayed using HUGO Nomenclature for DICER1 transcript
NM_177438.2Negative: no evidence of loss of function mutation or deleterious missense mutation classified by Sift score o0.10.
aCases recorded as CPDN in CHTN database. Original pathology reports submitted with these cases indicated a diagnosis of CPDN, but
microscopic descriptions indicated no primitive nephroblastic elements. Central review was requested from pathologist blinded to genetic data
(EP) who indicated these tumors did not contain primitive nephroblastic elements and thus were more appropriately classified as CN. Previous
abstract presentation did not include this information.
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child who subsequently developed pleuropulmon-
ary blastoma showed an unusual multipatterned
neoplasm with blastema, cartilage, differentiated
skeletal muscle, anaplasia, and primitive epithelial
tubules (Figure 1). Immunohistochemistry for WT1
showed strong nuclear staining in the epithelial
components. Next generation sequencing on
formalin-fixed, paraffin-embedded tissue from
the pleuropulmonary blastoma in this child
identified a germline loss of function DICER1
mutation (c.1732dupA; p.Thr578Asnfs*6) and a
somatic missense mutation (p.E1813D). Similar
analysis of tissue from the Wilms tumor detected
the loss of function DICER1 mutation c.1732dupA
but did not identify a missense mutation in a
common hotspot region. Follow-up Sanger sequen-
cing with small primers designed for hotspot
mutation detection was also negative. No slides
or DNA were available from the other two Registry
cases.
Pathology of Four Cystic Nephroma-Associated Renal
Sarcomas
Over the past year, the Registry has had the oppor-
tunity to review four examples of renal sarcomas
associated with cystic nephroma.
Case 1. A 15-year-old male had a past history of
‘multifocal cystic adenomatoid malformations’ of the
right and left lungs at age of 7 months, which was
followed by bilateral cystic nephromas at 18 months
of age treated with wedge excisions. He was well
until 10 years of age when a left renal mass was
detected and a nephrectomy was performed. This
neoplasm was a high-grade sarcoma with blastema,
spindle cell and anaplastic elements seemingly
arising beneath the renal pelvic urothelium
(Figure 2). Vascular invasion was identified within
the renal hilum. No primitive tubular/epithelial
components were identified. Residual cystic nephro-
ma was seen adjacent to the malignant component.
The tumor was interpreted as an ‘anaplastic Wilms
tumor.’ At age 13 years and again at 15 years, he
p r e s e n t e dw i t hr e c u r r e n ta b d o m i n a lm a s s e sw i t ha
high-grade sarcomatous morphology. Material was
not available for DICER1 testing.
Case 2. A 20-year-old female was found to have a
6.8-cm multilocular cystic renal mass, which was
resected in a piecemeal manner. Multiple cysts lined
by cuboidal/hobnail epithelium with a subepithelial
condensation of primitive mesenchymal spindle
cells with a cambium layer-like appearance were
the histologic features (Figure 3). Focal areas with
undifferentiated spindle cells with marked atypia
were also present. Approximately 11 months later,
omental and cul de sac masses were discovered,
these masses had high-grade anaplastic sarcomatous
features similar to the atypical areas seen in the renal
cystectomy specimen. Mutation analysis was per-
formed on frozen tumor tissue and showed DICER1
nonsense mutation in exon 14 (c.2233C4T; p.
Arg745*) and a missense hotspot mutation
(c.5437G4A; p.Glu1813Lys). There was also a TP53
mutation in exon 7 (c.731G4A; p.G244D) affecting
the transactivational domain and predicted to be
deleterious by SIFT. The TP53 variant allele fre-
quency was 97% suggesting loss of the wild-type
allele. Cytogenetics showed a complex karyotype
Table 2 Clinicopathologic features of cystic nephroma cases
from International Pleuropulmonary Blastoma Registry
Number of patients 34
PPB patients 19
Relatives 8
Associated Diseases 7
DICER1a
Positive 13 72%
Negative 5 28%
Unknown 16
Gender
Males 18 53%
Females 16 47%
Age at CN Diagnosisb
Median 19 (Range 0–54) months
Lateralityc
Left 11 37%
Right 11 37%
Bilateral 9 26%
Unknown 4
Surgeryd
Nephrectomy 18 53%
Partial Nephrectomy 8 24%
One-sided partial other
complete
13 %
No surgery (died of PPB) 1 3%
Unknown 6 17%
Complications
Renal Transplantation 2 6% (alive 5.5–7 years
after CN )
Survival
Death (Both PPB related) 2 6%
Alive 32 94%
Follow-up
Median 4.6 (Range 0–47) years
PPB Typee
I 9 26%
Ir 4 12%
II 6 18%
Cysts in the lungs (PPB
Type Ic)
39 %
No PPB 12 35%
aPercentage calculated from known DICER1 status.
bExcluding patient whose age 179 months is an outlier.
cPercentage is calculated on number of known sidedness (n¼30).
dPercentage is calculated excluding one patient with both procedures
and one patient who did not have any surgery.
eOf the known PPB 16/22 (73%) were cystic and 6/22 (27%) Type II,
none had Type III.
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ities including allelic loss of chromosome 17.
Case 3. A 26-month-old female with a 940 gram
cystic and solid renal neoplasm had been reported
previously as a dedifferentiated cystic nephroma
with malignant mesenchymoma.18 The mother had
noted an abdominal mass 3 months before surgery,
but also stated that an increased abdominal girth
was present for approximately a year. The main
component of the tumor was multilocular, with
cysts ranging from 0.1 to 3cm in diameter. The cysts
were lined by flattened, cuboidal or hobnail
epithelium with thin septa of varying cellularity.
There were multiple subepithelial areas of primitive
cells or spindle cells without expansile tumor
growth. A 7 5 4cm 3 solid area was composed of
primitive skeletal muscle, small primitive
embryonal cells, malignant cartilage, and anaplasia
(Figure 4). Immunohistochemistry for WT1 showed
cytoplasmic staining in the primitive embryonal and
skeletal muscle components. No primitive tubular/
epithelial elements were seen. She was alive with-
out disease 18 years after diagnosis. DICER1 sequen-
cing on both germline DNA and formalin-fixed,
paraffin-embedded tissue did not identify either a
deleterious loss of function mutation or a hotspot
somatic missense mutation.
Case 4. A 21-month-old girl had a 6.6cm cystic
and solid mass of the left kidney, which was
composed of multiple cysts lined by cuboidal/
hobnail epithelium with loose subepithelial me-
senchyme without overtly sarcomatous features, but
in adjacent areas there was a spindle cell sarcoma
pattern with anaplasia and pleomorphism
(Figure 5). No primitive tubular or other epithelial
elements were seen. Immunohistochemically, the
immature mesenchyme and solid sarcomatous foci
were reactive for desmin, and there was no nuclear
WT1 expression. DICER1 testing on formalin-fixed,
paraffin-embedded tumor tissue identified a
c.5427G4A; G1809R somatic missense mutation.
Figure 1 Unusual Wilms tumor in patient with germline DICER1 mutation and subsequent PPB. (a) Sheets of loose primitive blastemal
cells and nodules of cartilage, (b) Primitive cartilage nodule emerging from primitive mesenchyme on left; (c) primitive spindled cells
with skeletal muscle differentiation; (d) array of primitive tubules resembling seen primitive tubules in classic Wilms tumor (H&E;
original magnification  200 (a–d).
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Cystic and multicystic lesions of the kidney
encompass a broad pathogenetic spectrum rang-
ing from inherited, developmental to neoplastic
processes. Circumscribed multicystic lesions in
the kidney in the pediatric age group include cystic
nephroma and cystic partially differentiated
nephroblastoma as representatives of the Wilms tumor
spectrum.2–3,19 Although both cystic nephroma and
Figure 2 Malignant transformation of cystic nephroma in a 10 year-old boy. (a) Low power view of complex cystic spaces and variable
stromal cellularity; (b) medium power view of cyst septa lined by plump, cuboidal, ‘hobnail,’ epithelium with subepithelial layer of
primitive cells (cambium layer). This pattern is remarkably similar to the Type I, cystic PPB. (c, d) High power views of atypical,
primitive cells beneath the epithelium; (e, f) recurrent solid tumor with spindle cell sarcomatous and anaplastic patterns ((H&E; original
magnification  100 (a),  200 (b, e);  400 (c, d, f)).
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indistinguishable on gross examination, the presence
of microscopic ‘immature’ nephroblastic elements
differentiates the latter from cystic nephroma.2,19
There has been considerable discussion in the
recent past literature about the histogenetic relation-
ship between cystic nephroma and another multi-
cystic tumor of the kidney, mixed epithelial, and
stromal tumor.20,21 Recent pathologic and molecular
studies have served to promote the idea that these
two cystic neoplasms are closely related entities on
the basis of morphology, immunohistochemistry,
and gene expression; the multicystic architecture
and the approximation of the epithelial lining of the
cysts and the underlying septal stroma are the basic
morphologic similarities.20,21 There is a proposed
unifying designation for these tumors as ‘renal
epithelial and stromal tumor.’20 An alternative
position states that ‘adult cystic nephroma is
distinct from pediatric cystic nephroma, which is
considered to be part of the spectrum of Wilms.’21
The present study is based upon the observation
of the association between cystic nephroma and
pleuropulmonary blastoma in children especially in
light of heterozygous germline mutations in DICER1
in affected kindreds.8,22 It has become apparent that
cystic nephroma and the purely cystic (type I)
pleuropulmonary blastoma are morphologically
similar in their composition of epithelial-lined
cysts and subepithelial mesenchyme as well as
occurring primarily in children two years of age or
less.23 Mouse models with conditional biallelic
DICER1 ablation in distal lung epithelium
and ureteric bud epithelium have recapitulated
the human phenotype of cystic (type I) pleuro-
pulmonary blastoma and cystic nephroma,
respectively.24–26 One notable difference between
cystic nephroma and pleuropulmonary blastoma is
the seemingly disproportionate risk for sarcomatous
transformation in the case of cystic (type I)
pleuropulmonary blastoma.27 This potential for
cystic or type I pleuropulmonary blastoma to
Figure 3 Malignant transformation of cystic nephroma in a 20 year-old woman. (a) Low power view of renal mass with variably sized
cystic spaces and focal areas of increased stromal cellularity; (b) medium power view of cyst with plump cuboidal epithelium and loose
subepithelial mesenchyme; (c) medium power view of septa lined by plump cuboidal epithelium and subepithelial collection of
primitive cells (cambium layer); (d) recurrent solid tumor with diffuse anaplasia ((H&E; original magnification  100 (a),  400 (b, d);
 200 (c)).
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the type II and III pleuropulmonary blastomas is
well established, but it is not a constant feature and
may in fact occur in only a small proportion
of cystic (type I) pleuropulmonary blastoma in
DICER1 mutation-positive individuals.23 If
malignant transformation in cystic pleuropul-
monary blastoma is less common than we have
supposed that cystic nephroma and pleuropu-
lmonary blastoma are so closely related in their
genetic pathogenesis, then we should not be
surprised that a small fraction of cystic nephromas
Figure 4 Malignant transformation of cystic nephroma in a 26-month-old child. (a) Low power view showing multiple rounded cysts
with increased septal cellularity; (b) high power view showing subepithelial spindle cell proliferation; (c) nodules of primitive cells
intermixed with loose rhabdomyosarcomatous tumor tissue; (d) area with more advanced skeletal muscle differentiation; (e, f) nodules of
malignant cartilage in background of anaplastic sarcoma (H&E; original magnification  100 (a),  400 (b, d, e, f),  200 (c)).
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gression. If this model of progression of cysts to
sarcoma is valid, renal sarcomas arising in asso-
ciation with cystic nephromas should be high-grade,
anaplastic and multipatterned, and indistingui-
shable in most respects from the solid, sarcoma-
tous component of pleuropulmonary blastoma.23,27
It was our premise that a DICER1 cystic nephroma
may have a sarcomatous counterpart like
pleuropulmonary blastoma. Similar to the initial
Figure 5 Renal sarcoma with cystic nephroma-like cysts in a 21 month old child. (a) Low power view of large cystic structures with
loose, pale subepithelial zone; (b, c) medium power view of cysts adjacent to solid sarcomatous areas; (d) high-grade spindle cell
sarcoma; (e) anaplastic tumor cells with markedly atypical enlarged, hyperchromatic nuclei and cytoplasmic hyaline globules; (f) desmin
immunohistochemistry highlighted cells in the anaplastic areas. (H&E; original magnification  100 (a),  200 (b, c),  400 (d, e); anti-
desmin immunostain  400 (f)).
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the literature before 1988, we believe that such renal
sarcomas have been reported under a variety of
appellations.28 One such report of 20 cases of
anaplastic sarcoma of the kidney is particularly
provocative; 10 of the patients in this report were
five years of age or less at diagnosis.29 A multi-
loculated cystic component with the features of
cystic nephroma was present in 7 of the 20 cases.
These authors appreciated that the sarcomatous
pattern in their cases showed a ‘similarity to the
pleuropulmonary blastoma.’29 Likewise, Faria and
Zerbini also noted that the sarcoma arising in their
case of a cystic nephroma resembled the pleuro-
pulmonary blastoma.18 Other categories including
embryonal sarcoma or embryonal rhabdomyo-
sarcoma of kidney may also include some DICER1
sarcomas.30–32 Certainly there is sufficient morpho-
logic overlap with anaplastic Wilms tumor that a
few of these high-grade renal neoplasms may have
been regarded as variants of anaplastic Wilms tumor.
Identification of a residual cystic nephroma compo-
nent with or without a cambium layer would be a
clue to the diagnosis if present, but, given the
experience with pleuropulmonary blastoma, solid or
type III pleuropulmonary blastomas do not have
residual cystic elements and possibly not all
pleuropulmonary blastomas progress from a cystic
stage, but this progression from a cystic stage to a
solid primitive sarcoma has been observed in a
number of Registry cases.
On the basis of (1) the identification of DICER1
RNase IIIb missense mutations in 18/20 (90%) cystic
nephromas, but in none of the cystic partially
differentiated nephroblastoma (P¼0.0001) is one
compelling point;33,34 (2) the younger median age of
cystic partially differentiated nephroblastoma in our
group of cases and in a larger series (median
age 12 months) than the age of children with cystic
nephroma (median age 18 months), in contrast to
age-linked multi-step genetic progression such as
seen in pleuropulmonary blastoma,2,19 and (3)
the striking morphological differences between
the sarcomas associated with cystic nephroma
and typical Wilms tumor, we have concluded that
cystic nephroma in children is not part of the
same pathogenetic spectrum as cystic partially
differentiated nephroblastoma and Wilms tumor
as generally accepted in the literature. Joshi and
Beckwith19 have defined cystic partially differen-
tiated nephroblastoma as a cystic lesion similar
in appearance to cystic nephroma, but containing
‘immature’ blastemal elements; however, they
also note that there are ‘gray-zone’ tumors with
poorly differentiated stroma and no blastemal
cells. We propose that some of these gray-zone
tumors lacking primitive nephrogenic elements
may actually be cystic nephromas, which have
undergone malignant progression in a manner
similar to the cystic (type I) pleuropulmonary
blastoma.27
Recently, a potential relationship between DICER1
mutations and Wilms tumor has been sug-
gested.2,35,36 As an organ-based embryonal tumor
with many features similar to pleuropulmonary
blastoma, a pathogenetic link between pleuro-
pulmonary blastoma and Wilms tumor would be
compelling. However, unlike pleuropulmonary
blastoma, familial Wilms tumor is quite uncom-
mon (only 1-2% of all cases) and has been linked to
mutations/deletions in WT1 (11p13), FWT1 (17q12)
and FWT2 (19q13) but not 14q 32.13 where DICER1
is located.37 Three studies to date have reported
results on DICER1 testing in individuals with Wilms
tumor; one of these found no DICER1 mutations in
the germline DNA from 50 patients.22 The second
study identified a truncating mutation in DICER1 in
germline DNA from 1 (0.4%) of 243 patients with
Wilms tumor.35 Interestingly, this patient later
developed bilateral Sertoli-Leydig cell tumors of
the ovary, one of the extrapulmonary neoplasms in
the DICER1—pleuropulmonary blastoma familial
tumor predisposition syndrome.11 Wu and collea-
gues36 performed whole gene DICER1 sequencing on
tumor tissue from 120 sporadic Wilms tumor and
targeted sequencing of the RNase IIIa and IIIb
domains on 71 formalin-fixed, paraffin-embedded
Wilms tumors; five missense or deleterious
mutations in four Wilms tumors (2.6%) were
identified. Upon closer review, only one of these
four Wilms tumor had detectable biallelic DICER1
variants; this case (case N) had two somatic
mutations in trans involving the RNase IIIb
domain (c.5438A4G and c.5452G4A); c.5438
A4G affects a common hotspot amino acid
E1813G seen in pleuropulmonary blastoma and
cystic nephroma.36 These authors noted the
presence of clones from this tumor with neither
mutation suggesting that these mutations were
subclonal, occurring later in tumorigenesis. The
other three cases described contained a benign
change p.I110V (case X), a single 5330T4A;
p.L1777H involving RNase IIIb domain (case M),
and a germline missense single-nucleotide polymor-
phism c.2614G4A;p.A872T (rs149242330; MAF
0.009) in a patient with biallelic WT gene deletion/
mutation and WAGR syndrome (case C). It would be
difficult to ascertain if the heterozygous DICER1
mutation was additive to the WT1 gene
abnormalities in the development of this Wilms
tumor in this child.
The Registry has identified one child with a
Wilms tumor who subsequently developed pleur-
opulmonary blastoma and three family members of
children with pleuropulmonary blastoma. One
family member with a Wilms tumor did not have a
DICER1 mutation, whereas her child with pleuro-
pulmonary blastoma inherited the germline DICER1
mutation from the paternal side. This case high-
lights the need for caution in presuming that all
examples of a particular neoplasm within a pleur-
opulmonary blastoma family are necessarily attribu-
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pleuropulmonary blastoma associated Wilms tumor
was reviewed by Registry pathologists; this renal
neoplasm had some unusual histologic features
for a Wilms tumor but showed nuclear positivity
for WT1. Sequencing of this tumor identified
the germline loss of function mutation, but hotspot
missense mutations were not identified despite
adequate coverage of those regions. Photomicro-
graphic documentation of DICER1-related Wilms
tumor was not provided in the other large
studies;22,36 however, the morphologic characteri-
zation of the Wilms tumor in the report of Slade
et al35 was described as having the typical features
of Wilms tumor (Personal communication, Kathy
Pritchard-Jones, 2013). The three hereditary
Wilms tumors described by Foulkes and Wu
were described as ‘triphasic’; one tumor had
anaplasia.22,38 Pathologic review of additional
cases may provide insight as to whether or not
DICER1-mutated Wilms tumors are morphologically
unique. It is notable that only two in five Wilms
tumors with loss of function DICER1 mutations also
had somatic RNase IIIb mutations.36 Additional
studies in this area are necessary to obtain a full
understanding of the role of DICER1 mutations in
the development of Wilms tumor.
Pleuropulmonary blastoma and cystic nephroma
represent a spectrum of abnormal organogenesis
affecting both the lung and kidney, respectively. The
genetic analyses presented here confirm that DI-
CER1 mutations have a major genetic role in the
pathogenesis of cystic nephroma in children.
Further, cystic nephroma and pleuropulmonary
blastoma have a similar DICER1 truncating and
‘hotspot’ missense mutation rates, which involve
specific amino acids in the RNase IIIb domain.9
Rather than cystic nephromas in children as
representing the benign end of the Wilms tumor
spectrum, we propose an alternative pathway with
the genetic pathogenesis of cystic nephroma and
renal sarcoma following a similar model of cystic
(type I) pleuropulmonary blastoma to the sarco-
matous type II/III tumors.23,27 Three of the four renal
sarcomas described here showed clinical or genetic
manifestations of the DICER1 syndrome and we
would propose naming this entity ‘DICER1 renal
sarcoma.’
Although most children with cystic nephroma in
the Registry cohort did very well, two children died
of pleuropulmonary blastoma and two others re-
quired bilateral nephrectomies and renal transplan-
tation at 9 and 42 months of age.17 We only
have long-term follow-up for one of the children
with renal sarcomas described here, but we
anticipate given the genetic and morphologic
similarities to cystic and solid pleuropulmonary
blastoma that the prognosis and response to therapy
may also be similar. Review of additional cases with
detailed clinical and genetic information would be
informative.
Although the traditional approach to a child with
a diagnosed cystic nephroma is to forego chemother-
apy,33 rapidly growing, bilateral cysts in an infant
present a management challenge. We have observed
in one patient treated with chemotherapy for cystic
(type I) pleuropulmonary blastoma in whom the
progressive growth of bilateral renal cysts was
arrested, averting the need for transplantation.
While this is only a single case, it may suggest a
beneficial role for chemotherapy; however, there is
insufficient data at the present to warrant any
therapeutic recommendations.
The presence of cystic neprhoma or renal sarcoma
in a child or young adult should alert the clinician
to the possibility of a germline mutation in DICER1
and the associated risk for pleuropulmonary blas-
toma and other associated conditions in the proband
and/or family members. Appropriate genetic coun-
seling and testing should be offered to the potential
proband and family, and screening for lung
lesions of a cystic or solid nature should be
considered based on age and DICER1 testing.38
Similarly, children diagnosed with pleuropul-
monary blastoma or DICER1 mutation should have
serial periodic ultrasound evaluations of the
kidneys as cystic nephroma may grow rapidly and
early intervention may limit the damage to normal
renal parenchyma. Unlike in the case of pleuro-
pulmonary blastoma, there are no current recomme-
ndations as to the frequency and longevity of
imaging studies in the case of cystic nephroma
and/or subsequent development of renal sarcomas
within cystic nephroma. The renal sarcomas appear
to have a broader age range at diagnosis than pleuro-
pulmonary blastoma. The risk for transformation or
progression, responsiveness to chemotherapy and
ultimate outcome are all unknown. To better
understand this disease and to develop appropriate
education and screening guidelines for individuals
and families, we encourage our pathology and clini-
cal colleagues to refer cases to the renal tumor
biology studies of the Children’s Oncology Group
and the longitudinal study of DICER1—pleuro-
pulmonary blastoma tumor predisposition study in
progress at the National Cancer Institute.39
Acknowledgments
This work is supported by National Institutes of
Health grants U10 CA98543 and U24 CA114766 to
the Children’s Oncology Group. Tissue samples
were provided by the Cooperative Human Tissue
Network that is funded by the National Cancer
Institute (NCI). Other investigators may have re-
ceived samples from these same tissues. Dr Hill,
Doros and Dr Rossi were supported in part by NCI
R01CA143167, an American Society of Clinical
Oncology Young Investigator Award (LD), The
Parson’s Foundation (DAH) and a grant from
Hyundai Hope on Wheels. We thank the many
physicians and families who contribute time and
Modern Pathology (2014) 27, 1267–1280
DICER1 Mutations and risk for tumors of the kidney
1278 L Doros et altissues that facilitate research, in particular the
members of the Renal Tumor Biology Committee of
the Children’s Oncology Group.
Disclosure/conflict of interest
The authors declare no conflict of interest.
References
1 Boggs LK, Kimmelstiel P. Benign multilocular
cystic nephroma: Report of two cases of so-called
multilocular cyst of the kidney. J Urol 1956;76:
530–541.
2 Joshi VV, Banerjee AK, Yadav K, et al. Cystic partially
differentiated nephroblastoma: a clinicopathologic
entity in the spectrum of infantile renal neoplasia.
Cancer 1977;40:789–795.
3 Murphy WM, Grignon DJ, Perlman EJ. Tumors of the
kidney, bladder and related urinary structures.
Washington DC. American Registry of Pathology
2004;1:47–49.
4 Delahunt B, Thomson KJ, Ferguson AF, et al. Familial
cystic nephroma and pleuropulmonary blastoma.
Cancer 1993;71:1338–1342.
5 Priest JR, Watterson J, Strong L, et al. Pleuropulmonary
blastoma: a marker for familial disease. J Pediatr 1996;
128:220–224.
6 Bal N, Kayaselcuk F, Polat A, et al. Familial cystic
nephroma in two siblings with pleuropulmonary
blastoma. Pathol Oncol Res 2005;11:53–56.
7 Boman F, Hill DA, Williams GM, et al. Familial
association of pleuropulmonary blastoma with cystic
nephroma and other renal tumors: A report from
the International Pleuropulmonary Blastoma Registry.
J Pediatr 2006;149:850–854.
8 Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations
in familial pleuropulmonary blastoma. Science 2009;
325:965.
9 Pugh TJ, Yu W, Yang J, et al. Progressive biallelic loss
of TP53 is associated with progression of pleuropul-
monary blastoma initiated by germline loss and
somatic mutation of DICER1. American Association
of Cancer Researchers Annual Meeting, 2013 Washing-
ton, DC, USA.
10 Heravi-Moussavi A, Anglesio MS, Cheng SW, et al.
Recurrent somatic DICER1 mutations in nonepithelial
ovarian cancers. N Engl J Med 2012;366:234–242.
11 Schultz KA, Pacheco MC, Yang J, et al. Ovarian sex
cord-stromal tumors, pleuropulmonary blastoma and
DICER1 mutations: a report from the International
Pleuropulmonary Blastoma Registry. Gynecol Oncol
2011;122:246–250.
12 Thorvaldsdo ´ttir H, Robinson JT, Mesirov JP. Integrative
genomics viewer (IGV): high-performance genomics
data visualization and exploration. Briefing Bioinfor-
matics 2013;14:178–192.
13 Robinson JT, Thorvaldsdo ´ttir H, Winckler W, et al.
Integrative Genomics Viewer. Nat Biotechnol 2011;29:
24–26.
14 Seal RL, Gordon SM, Lush MJ, et al. Genenames.org:
the HGNC resources in 2011. Nucleic Acids Res
2011;39(Database issue):D514–D519.
15 Ng PC, Henikoff S. Predicting deleterious amino acid
substitutions. Genome Res 2001;11:863–874.
16 Sim NL, Kumar P, Hu J, et al. SIFT web server:
predicting effects of amino acid substitutions on
proteins. Nucleic Acids Res 2012;40(Web Server
issue):W452–W457.
17 Shaheen IS, Fitzpatrick M, Brownlee K, et al. Bilateral
progressive cystic nephroma in a 9-month-old male
infant requiring renal replacement therapy. Pediatr
Nephrol 2010;25:1755–1758.
18 Faria PA, Zerbini MC. Dedifferentiated cystic nephro-
ma with malignant mesenchymoma as the dediffer-
entiated component. Pediatr Pathol Lab Med 1996;16:
1003–1011.
19 Joshi VV, Beckwith JB. Multilocular cyst of the kidney
(cystic nephroma) and cystic partially differentiated
nephroblastoma. Terminology and criteria for diagno-
sis. Cancer 1989;64:466–479.
20 Turbiner J, Amin MB, Humphrey PA, et al. Cystic
nephroma and mixed epithelial and stromal tumor of
kidney: a detailed clinicopathologic analysis of 34
cases and proposal for renal epithelial and stromal
tumor (REST) as a unifying term. Am J Surg Pathol
2007;31:489–500.
21 Zhou M, Kort E, Hoekstra P, et al. Adult cystic
nephroma and mixed epithelial and stromal tumor of
the kidney are the same entity. Molecular and
histologic evidence. Am J Surg Pathol 2009;33:72–80.
22 Bahubeshi A, Bal N, Rio Frio T, et al. Germline DICER1
mutations and familial cystic nephroma. J Med Genet
2010;47:863–866.
23 Hill DA, Jarzembowski JA, Priest JR, et al. Type I
pleuropulmonary blastoma: pathology and biology
study of 51 cases from the International Pleuropul-
monary Blastoma Registry. Am J Surg Pathol 2008;32:
282–295.
24 Harris KS, Zhang Z, McManus MT, et al. Dicer
function is essential for lung epithelium morphogen-
esis. Proc Natl Acad Sci USA 2006;103:2208–2213.
25 Nagalakshmi VK, Ren Q, Pugh MM, et al. Dicer
regulates the development of nephrogenic and ureteric
compartments in the mammalian kidney. Kidney Int
2011;79:317–330.
26 Pastorelli LM, Wells S, Fray M, et al. Genetic analyses
reveal a requirement for Dicer1 in the mouse urogenital
tract. Mamm Genome 2009;20:140–151.
27 Priest JR, McDermott MB, Bhatia S, et al. Pleuropul-
monary blastoma: a clinicopathologic study of 50
cases. Cancer 1997;80:147–161.
28 Manivel JC, Priest JR, Watterson J, et al. Pleuropul-
monary blastoma. The so-called pulmonary blastoma
of childhood. Cancer 1988;62:1516–1526.
29 Vujanic ´ GM, Kelsey A, Perlman EJ, et al. Anaplastic
sarcoma of the kidney: a clinicopathologic study of 20
cases of a new entity with polyphenotypic features.
Am J Surg Pathol 2007;10:1459–1468.
30 Delahunt B, Beckwith JB, Eble JN, et al. Cystic
embryonal sarcoma of kidney: a case report. Cancer
1998;82:2427–2433.
31 Sola JE, Cova D, Casillas J, et al. Primary renal botryoid
rhabdomyosarcoma: diagnosis and outcome. J Pediatr
Surg 2007;42:e17–e20.
32 Raney B, Anderson J, Arndt C, et al. Primary renal
sarcomas in the Intergroup Rhabdomyosarcoma Study
Group (IRSG) experience, 1972–2005: A report from
the Children’s Oncology Group. Pediatr Blood Cancer
2008;51:339–343.
Modern Pathology (2014) 27, 1267–1280
DICER1 Mutations and risk for tumors of the kidney
L Doros et al 127933 Luithle T, Szavay P, Furtwangler R, et al. SIOP/GPOH
Study Group. Treatment of cystic nephroma and
cystic partially differentiated nephroblastoma—a report
from the SIOP/GPOH study group. J Urol 2007;177:
294–296.
34 van den Hoek J, de Kriger R, van de Ven K, et al.
Cystic nephroma, cystic partially differentiated ne-
phroblastoma and cystic Wilms tumor in children: a
spectrum with therapeutic dilemmas. Urol Int 2009;82:
65–70.
35 Slade I, Bacchelli C, Davies H, et al. DICER1 syndrome:
clarifying the diagnosis, clinical features and
management implications of a pleiotropic tumour
predisposition syndrome. J Med Genet 2011;48:
273–278.
36 Wu M, Sabbaghian N, Xu B, et al. Biallelic DICER1
mutations occur in Wilms tumours. J Pathol 2013;230:
154–164.
37 Foulkes WD, Bahubeshi A, Hamel N, et al. Extending
the phenotypes associated with DICER1 mutations.
Hum Mutat 2011;32:1381–1384.
38 Hill DA, Doros L, Schultz KA, et al. DICER1 syndrome
disorders. In: Pagon RA, Adam MP, Bird TD, et al (eds).
Gene Reviews (Internet). Seattle, WA: University of
Washington, Seattle, 1993–2014, (in press, 2014)
Available from: http://www.ncbi.nlm.nih.gov/books/
NBK1116.
39 DICER1-related PPB studydceg.cancer.gov/research/
clinical-studies/dicer1-ppb-study.
This work is licensed under a Creative
Commons Attribution-NonCommercial-
ShareAlike 3.0 Unported License. To view a copy of
this license, visit http://creativecommons.org/li-
censes/by-nc-sa/3.0/
Modern Pathology (2014) 27, 1267–1280
DICER1 Mutations and risk for tumors of the kidney
1280 L Doros et al